Summit Therapeutics Inc. vs Novavax, Inc.: SG&A Expense Trends

SG&A Expense Trends: A Tale of Two Biotechs

In the dynamic world of biotechnology, understanding financial trends is crucial. Over the past decade, Summit Therapeutics Inc. and Novavax, Inc. have shown contrasting trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Novavax's SG&A expenses surged by over 2,250%, peaking in 2022. This reflects their aggressive expansion and increased operational activities, especially during the COVID-19 pandemic. In contrast, Summit Therapeutics exhibited a more modest growth of approximately 315% in the same period, indicating a more conservative approach. The year 2020 marked a significant leap for both companies, with Novavax's expenses increasing by 322% and Summit's by 107% compared to the previous year. These trends highlight the strategic differences in managing operational costs, with Novavax focusing on rapid scaling and Summit maintaining steady growth. Investors and stakeholders should consider these patterns when evaluating the companies' financial health and strategic direction.